Literature DB >> 6345756

Metabolic disposition of prostacyclin in humans.

A R Brash, E K Jackson, C A Saggese, J A Lawson, J A Oates, G A FitzGerald.   

Abstract

Quantitative analysis of metabolite levels is a useful approach to investigation of the in vivo synthesis of short-lived mediators such as prostacyclin (PGI2). In order to establish the basis for metabolite assays of PGI2, we have studied the fate of radiolabeled PGI2 administered to man. Three healthy male volunteers each received i.v. 11 beta-[3H]PGI2 at 4 ng/kg/min for 24 hr. A gradual increase in plasma radioactivity was observed throughout the infusion period, followed by a biphasic decline postinfusion (T 1/2 alpha, 53 min; T 1/2 beta, 246 min) suggestive of the presence of long-lived metabolites of PGI2 in the circulation. The recovery of radioactivity averaged 82% in urine and, in contrast to other species, only 4% in feces. Direct analysis of urine by high-pressure liquid chromatography revealed the presence of at least 16 compounds and documented their relative abundance. Ten compounds were subsequently identified by gas chromatography-mass spectrometry. All identified metabolites retained the 6-keto-prostaglandin F structure characteristic of PGI2 hydrolysis and were each formed in less than 10% yield from administered PGI2. Of interest was the finding that 6-keto-prostaglandin F1 alpha accounted for 5.9% of systemically administered 11 beta-[3H]PGI2. These results identify urine as the major route of human PGI2 metabolite excretion and also illustrate the utility of direct chromotographic analysis of urine in the elucidation of prostaglandin disposition in humans.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345756

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Prostaglandins in osteoid osteoma.

Authors:  F Greco; F Tamburrelli; G Ciabattoni
Journal:  Int Orthop       Date:  1991       Impact factor: 3.075

2.  A nonapoptotic role for BAX and BAK in eicosanoid metabolism.

Authors:  Tejia Zhang; Loren D Walensky; Alan Saghatelian
Journal:  ACS Chem Biol       Date:  2015-04-06       Impact factor: 5.100

3.  Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  In vivo Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy.

Authors:  Zhimin Wang; Raymond L Benza; Lee Zourelias; Angela Sanguino; Ramaz Geguchadze; Kelly J Shields; Changgong Wu; Kristin B Highland; Michael J Passineau
Journal:  Hum Gene Ther       Date:  2017-08       Impact factor: 5.695

5.  Response to bosentan in children with pulmonary hypertension.

Authors:  S Maiya; A A Hislop; Y Flynn; S G Haworth
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

6.  Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.

Authors:  Pamela L Rice; Bradley S Barrett; Jason M Fritz; Mary C Srebernak; Lori R Kisley; Alvin M Malkinson; Lori D Dwyer-Nield
Journal:  Exp Lung Res       Date:  2010-11       Impact factor: 2.459

Review 7.  Prostaglandins, the kidney, and hypertension.

Authors:  T W Wilson; R D Kaushal; M Dubois
Journal:  West J Med       Date:  1990-08

Review 8.  Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.

Authors:  Melissa Gabbs; Shan Leng; Jessay G Devassy; Md Monirujjaman; Harold M Aukema
Journal:  Adv Nutr       Date:  2015-09-15       Impact factor: 8.701

9.  Cyclosporin reduces renal prostanoid excretion in type 1 diabetic patients.

Authors:  V A Koivisto; M Leirisalo-Repo; R Pelkonen; U Turunen; J Rapola; L Viinikka; O Ylikorkala
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

10.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.